A Study to Learn About the Benefit of Rimegepant Versus Triptans in Migraine Buddy App Users.

Part of paid clinical trials in New York, New York.

Sponsor
Pfizer
Study ID
NCT06532357
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

The purpose of this study is to collect information of the US users from the Migraine Buddy app between 20 October 2023 and 20 May 2024. Patients who used Nurtec and/or triptans as an acute treatment for migraine, with or without a background of preventive treatment (anti-CGRP, Botox or oral migraine preventive medications) and completed a survey were eligible for this study. Acute treatment is a short-term treatment. The aim of this retrospective analysis was to learn about the user´s satisfaction with Nurtec or the triptan. The level of satisfaction with Nurtec will be compared to the level of satisfaction with triptans. The benefit of this study is the real-life setting of the information collected. This means that the users were using the Migraine Buddy app for tracking their migraines in real life.

Key Dates

Start date
Jun 9, 2024
Status verified
Aug 2025
Primary completion
Jun 10, 2024
Completion
Jun 10, 2024

Study Design

Enrollment
1,536 participants (actual)

Primary Outcome Measure

Number of Participants Classified as Per Responses for Satisfaction of Pain Intensity [ Time Frame: Up to 60 days post last usage of treatment (from retrospective data collection period of 7 months); available retrospective data was evaluated in this observational study of a single day ]

Locations (1)

FacilityCityStateZIPSite coordinators
PfizerNew YorkNew York10001-

Find similar trials in New York, NY

By condition
Migraine
By specialty
Neurology
By research site
Pfizer· New York, NY

Related Studies